- Drug Pipelines
- February 2024
- 180 Pages
Global
From €2900EUR$3,000USD£2,491GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Report
- January 2022
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- November 2019
- 61 Pages
Global
From €3862EUR$3,995USD£3,318GBP
- Report
- February 2020
- 173 Pages
Global
From €10630EUR$10,995USD£9,130GBP
The HER2 Negative Breast Cancer Drug market is a subset of the larger Breast Cancer Drug market. HER2 Negative Breast Cancer Drugs are used to treat breast cancer that does not express the HER2 protein. These drugs are typically used in combination with other treatments such as chemotherapy, radiation, and hormone therapy. Commonly used HER2 Negative Breast Cancer Drugs include aromatase inhibitors, cyclin-dependent kinase 4/6 inhibitors, and mTOR inhibitors. These drugs are used to reduce the risk of recurrence and improve overall survival rates.
Notable companies in the HER2 Negative Breast Cancer Drug market include AstraZeneca, Pfizer, Novartis, and Roche. These companies are involved in the research, development, and marketing of HER2 Negative Breast Cancer Drugs. Show Less Read more
